Trial reportPharmacoEconomics2000
Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia.
Trial report in PharmacoEconomics, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.PLoS computational biology · 2021Article
- Article
- Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.PharmacoEconomics · 2018Article
- Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic.Vaccine · 2018Article
- Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in Turkey.PloS one · 2016Article
- An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine.Vaccine · 2015Article
- Connecting within and between-hosts dynamics in the influenza infection-staged epidemiological models with behavior change.Journal of coupled systems and multiscale dynamics · 2015Article
- Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Quantifying the economic value and quality of life impact of earlier influenza vaccination.Medical care · 2015Article
- Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.Human vaccines & immunotherapeutics · 2015Article
- Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.BMC infectious diseases · 2014Article
- Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents.ClinicoEconomics and outcomes research : CEOR · 2012Article
- To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling.PloS one · 2010Article
- Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model.Obstetrics and gynecology · 2009Article
- Review
- A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.PharmacoEconomics · 2006Article
- Gaining insights into human viral diseases through mathematics.European journal of epidemiology · 2006Review
- Antiviral agents for influenza: a comparison of cost-effectiveness data.PharmacoEconomics · 2005Review
- Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children.Clinical drug investigation · 2004Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo use data from a clinical trial of zanamivir, a new antiviral drug, to estimate the costs and effectiveness of alternative treatment strategies for a high-risk population in Australia visiting a physician for treatment of influenza or influenza-like illness within 36 hours of symptom onset. DESIGN AND
settingThis was a modelling study using data from a randomised, double-blind, placebo-controlled trial with centres in Australia, New Zealand and South Africa. Cost data were taken from standard Australian sources.
methodsEfficacy data from the clinical trial were used to populate a computer model designed to estimate the costs and health outcomes associated with alternative treatments for influenza and influenza-like illness. Only patients who consulted the physician within 36 hours of symptom onset were included in this trial. Cost data were used to translate the clinical data into treatment cost estimates.
resultsTreatment with zanamivir for this high risk population results in an incremental cost of $A14.20 per day of symptoms avoided in the base case. The cost per quality-adjusted life-year (QALY) gained is $A11,715. The results are sensitive to several parameter values, including the influenza-positive rate and the impact of zanamivir on days to alleviate symptoms and hospitalisation.
conclusionsInfluenza is costly for the high risk population who seek physician treatment. Treatment with zanamivir for this population is cost effective based on an $A78,000 per QALY benchmark. Zanamivir could be cost saving if it reduces the hospitalisation rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.